Cetya Therapeutics announces STTR grant
$240,000 Grant will allow evaluation of Cetya’s HDAC inhibitors for treatment of sickle cell disease.
$240,000 Grant will allow evaluation of Cetya’s HDAC inhibitors for treatment of sickle cell disease.
© 2018 · Cetya Therapeutics